Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($1.61), $0.20 worse than the analyst estimate of ($1.41). Revenue for the quarter came in at $0 versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.